|
Delayed
NYSE
04:00:00 2025-09-15 pm EDT
|
5-day change | 1st Jan Change | ||
| 8.610 USD | +0.23% |
|
-.--% | - |
| 25-09-17 | Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Microcap Index | CI |
| 25-09-17 | Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 3000E Index | CI |
| Market Cap | 391M 348M 324M 296M 558M 37.61B 563M 3.93B 1.52B 19.23B 1.47B 1.44B 61.7B | P/E 2023 |
-13.9x | P/E 2024 | -11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 325M 289M 269M 246M 463M 31.22B 467M 3.26B 1.26B 15.96B 1.22B 1.19B 51.23B | EV / Sales 2023 |
2,597,077x | EV / Sales 2024 | 3,242,111x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | +0.23% |
| 3 years | 3.55 |  | 20.9 |
| 5 years | 2.7 | | 29.24 |
| 10 years | 2.7 | | 55.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Vanessa Wolfeler
PSD | President | - | 2025-09-15 |
| Chief Tech/Sci/R&D Officer | 75 | 2015-12-31 | |
Daniel Dolan
TRE | Treasurer | - | 2025-09-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Vanessa Wolfeler
BRD | Director/Board Member | - | 2025-09-15 |
Robert Duffield
BRD | Director/Board Member | - | 2025-09-15 |
Daniel Dolan
BRD | Director/Board Member | - | 2025-09-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/16/25 | Tender | Chief Executive Officer | 1,336,523 | 2.9840% | ||
| 9/16/25 | Tender | Chairman | 178,850 | 0.3993% | ||
| 9/16/25 | Sofinnova Investments, Inc.
| Tender | Company | 2,194,278 | 4.8991% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 84.82 75.36 70.34 64.11 120.91 8.15K 122.04 851.21 329.84 4.17K 318.45 311.54 13.38K | 87.68 77.91 72.71 66.28 125 8.43K 126.16 879.97 340.99 4.31K 329.21 322.07 13.83K |
| Net income | -21.43M -19.04M -17.77M -16.2M -30.54M -2.06B -30.83M -215M -83.33M -1.05B -80.45M -78.7M -3.38B | -29.67M -26.36M -24.6M -22.42M -42.29M -2.85B -42.68M -298M -115M -1.46B -111M -109M -4.68B |
| Net Debt | -77.22M -68.61M -64.03M -58.37M -110M -7.42B -111M -775M -300M -3.79B -290M -284M -12.18B | -66.41M -59.01M -55.08M -50.2M -94.68M -6.38B -95.56M -667M -258M -3.26B -249M -244M -10.47B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- YMAB Stock
Select your edition
All financial news and data tailored to specific country editions
